European Journal of Pharmacology, 232 (1993) 327–329
© 1993 Elsevier Science Publishers B.V. All rights reserved 0014-2999/93/$06.00

Author index

Ahrén, B., see Gregersen, S. (232) 35
Angel, I., Schoemaker, H., Prouteau, M., Garreau, M. and Langer, S.Z.
Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT_3 receptor antagonist and antiemetic properties (232) 139
Anthony, T.L., see Knoper, S.R. (232) 65
Aoyagi, T., see Majima, M. (232) 181
Artigas, F., see Bel, N. (232) 326
Aurell, C.-J., see Vilhardt, H. (232) 223

Barnes, P.J., see Kato, M. (232) 7
Bartfai, T., see Gregersen, S. (232) 35
Barth, T., see Vilhardt, H. (232) 223
Bassi, L., see Cerri, M.A. (232) 291
Bast, A., see Ter Laak, A.M. (232) 199
Bazzoni, G., see Cerri, M.A. (232) 291
Beal, M.F., see Nozaki, K. (232) 295
Bel, N. and Artigas, F.
Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. European Journal of Pharmacology, 229 (1992) 101–103 (232) 326
Beltrán-Nuñez, A., see Cerri, M.A. (232) 291
Bemis, K.G., see Shannon, H.E. (232) 47
Benthem, L., Scheurink, A.J.W., Van der Leest, J., Leuvenink, H., Zijlstra, W.G. and Steffens, A.B.
Effects of long-term d-fenfluramine treatment on energy metabolism in rats (232) 279
Berkenbosch, A., Rupreht, J., DeGoede, J., Olievier, C.N. and Wolsink, J.G.
Effects of eseroline on the ventilatory response to CO_2 (232) 21
Bernasconi, S., see Cerri, M.A. (232) 291
Bidzseranova, A., Varga, J. and Telegdy, G.
The effects of brain natriuretic peptide-32 on electroconvulsive shock-induced amnesia in rats. The role of neurotransmitters (232) 305
Boldry, R.C., see Papa, S.M. (232) 247
Bomzon, A., see Pauletzki, J.G. (232) 263
Boucher, S., see Picard, P. (232) 255
Bouhassira, D., Chitour, D., Villanueva, L. and Le Bars, D.
Morphine and diffuse noxious inhibitory controls in the rat: effects of lesions of the rostral ventromedial medulla (232) 207
Boye, S.M., see Rompré, P.-P. (232) 299
Brown, C.M., see MacKinnon, A.C. (232) 79
Bymaster, F.P., see Shannon, H.E. (232) 47

Carrón, R., see Pérez-Vizcaíno, F. (232) 105
Cerletti, C., see Rotondo, S. (232) 41
Cerri, M.A., Beltrán-Nuñez, A., Bernasconi, S., Dejana, E., Bassi, L. and Bazzoni, G.
Inhibition of cytokine production and endothelial expression of adhesion antigens by 5′-methylthioadenosine (232) 291
Chase, T.N., see Papa, S.M. (232) 247
Chitour, D., see Bouhassira, D. (232) 207
Clapham, J. and Kilpatrick, G.J.
Histamine H_3 receptor-mediated modulation of water consumption in the rat (232) 99
Coggan, J.S., see Knoper, S.R. (232) 65
Cohen, G., see Evans, J. (232) 241
Couture, R., see Picard, P. (232) 255
Currie, P.J. and Wilson, L.M.
Potentiation of dark onset feeding in obese mice (genotype ob/ob) following central injection of norepinephrine and clonidine (232) 227
Czechowska, G., Dziki, M., Pietrasiewicz, T., Kleinrok, Z., Turski, W.A. and Czuczwar, S.J.
Competitive antagonists of NMDA receptors, CGP 37849 and CGP 39551, enhance the anticonvulsant activity of valproate against electroconvulsions in mice (232) 59
Czuczwar, S.J., see Czechowska, G. (232) 59

Davison, J.S., see Pauletzki, J.G. (232) 263
De Gaetano, G., see Rotondo, S. (232) 41
DeGoede, J., see Berkenbosch, A. (232) 21
Dejana, E., see Cerri, M.A. (232) 291
De Kloet, E.R., see Van Erp, A.M.M. (232) 217
Delpón, E., see Pérez-Vizcaíno, F. (232) 105
Donné-Op den Kelder, G.M., see Ter Laak, A.M. (232) 199
Duarte, J., see Pérez-Vizcaíno, F. (232) 105
Dziki, M., see Czechowska, G. (232) 59

Ellinwood, Jr., E.H., see Lee, T.H. (232) 125
Engber, T.M., see Papa, S.M. (232) 247
Evans, J. and Cohen, G.
Catecholamine uptake inhibitors elevate 6-hydroxydopamine in brain after administration of 6-hydroxydopa (232) 241

Finklestein, S.P., see Nozaki, K. (232) 295
Fischer, S., Wolf, G., Keilhoff, G. and Hass, P.
Mg^{2+} antagonizes α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-induced brain damage and convulsions (232) 121
Franks, R., see Guard, S. (232) 287
Fréhel, D., see Gully, D. (232) 13
Furman, B.L. and Sneddon, P.
Endothelium-dependent vasodilator responses of the isolated mesenteric bed are preserved in long-term streptozotocin diabetic rats (232) 29

Garreau, M., see Angel, I. (232) 139
Gitter, B.D., see Picard, P. (232) 255
Gregersen, S., Lindskog, S., Land, T., Langel, Ü., Bartfai, T. and Ahrén, B.
Blockade of galanin-induced inhibition of insulin secretion from isolated mouse islets by the non-methionine containing antagonist M35 (232) 35
Grundemar, L., Krstenansky, J.L. and Håkanson, R.
Activation of neuropeptide Y_1 and neuropeptide Y_2 receptors by substituted and truncated neuropeptide Y analogs: identification of signal epitopes (232) 271
Guard, S., Pain, D., Franks, R. and Watling, K.J.
[^{125}I]Neurokinin A labels pharmacologically distinct populations of NK_2 binding sites in hamster and rabbit urinary bladder (232) 287

Gully, D., Fréhel, D., Marcy, C., Spinazzé, A., Lespy, L., Neliat, G., Maffrand, J.-P. and Le Fur, G.
Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCK_A receptors (232) 13

Håkanson, R., see Grundemar, L. (232) 271
Hass, P., see Fischer, S. (232) 121
Heath, I., see Shannon, H.E. (232) 47
Holzer, P., see Lippe, I.T. (232) 113
Hönack, D., see Löscher, W. (232) 147
Howbert, J.J., see Picard, P. (232) 255

Kato, M., Tokuyama, K., Morikawa, A., Kuroume, T. and Barnes, P.J.
Platelet-activating factor-induced enhancement of superoxide anion generation in guinea-pigs (232) 7
Katori, M., see Majima, M. (232) 181
Keilhoff, G., see Fischer, S. (232) 121
Kilpatrick, G.J., see Clapham, J. (232) 99
Kleinrok, Z., see Czechowska, G. (232) 59
Knoper, S.R., Meehan, A.G., Purnyn, S., Coggan, J.S., Anthony, T.L. and Kreulen, D.L.
CCK_A receptors mediate slow depolarizations in cultured mammalian sympathetic neurons (232) 65
Kreulen, D.L., see Knoper, S.R. (232) 65
Krstenansky, J.L., see Grundemar, L. (232) 271
Kruk, M.R., see Van Erp, A.M.M. (232) 217
Kubes, P., see McCafferty, D.-M. (232) 169
Kuribayashi, Y., see Majima, M. (232) 181
Kuroume, T., see Kato, M. (232) 7
Kuttan, S.C. and Sim, M.K.
Angiotensin II-induced tachyphylaxis in aortas of normo- and hypertensive rats: changes in receptor affinity (232) 173

Land, T., see Gregersen, S. (232) 35
Langel, Ü., see Gregersen, S. (232) 35
Langer, S.Z., see Angel, I. (232) 139
Latifpour, J., see Yoshida, M. (232) 159
Le Bars, D., see Bouhassira, D. (232) 207
Lee, T.H., Ellinwood, Jr., E.H. and Zhang, H.
In vitro extracellular recording from nigral dopamine neurons following continuous d-amphetamine infusion (232) 125
Le Fur, G., see Gully, D. (232) 13
Lespy, L., see Gully, D. (232) 13
Leuvenink, H., see Benthem, L. (232) 279
Lindskog, S., see Gregersen, S. (232) 35
Lippe, I.T., Stabentheiner, A. and Holzer, P.
Participation of nitric oxide in the mustard oil-induced neurogenic inflammation of the rat paw skin (232) 113
Löscher, W. and Hönack, D.
Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats (232) 147

MacKinnon, A.C., Stewart, M., Olverman, H.J., Spedding, M. and Brown, C.M.
[^{3}H]p-Aminoclonidine and [^{3}H]idazoxan label different populations of imidazoline sites on rat kidney (232) 79
Maffrand, J.-P., see Gully, D. (232) 13
Majima, M., Shima, C., Saito, M., Kuribayashi, Y., Katori, M. and Aoyagi, T.
Poststatin, a novel inhibitor of bradykinin-degrading enzymes in rat urine (232) 181
Manzini, S., see Riccio, M.M. (232) 89
Marcy, C., see Gully, D. (232) 13
Martinez-Piñero, M.G., Vargas, M.L. and Milanés, M.V.
L-type Ca^{2+} channel ligands modulate morphine effects on the hypothalamus-pituitary-adrenocortical axis in rats (232) 191
McCafferty, D.-M., Kubes, P. and Wallace, J.L.
Inhibition of platelet-activating factor-induced leukocyte adhesion in vivo by a leumedin (232) 169
Meehan, A.G., see Knoper, S.R. (232) 65
Meehan, S.M., see Schechter, M.D. (232) 135
Melin, P., see Vilhardt, H. (232) 223
Milanés, M.V., see Martinez-Piñero, M.G. (232) 191
Mitch, C.H., see Shannon, H.E. (232) 47
Morikawa, A., see Kato, M. (232) 7
Mutabagani, K., see Tamura, K. (232) 235

Neliat, G., see Gully, D. (232) 13
Nishi, S., see Yamada, S. (232) 1
Nozaki, K., Finklestein, S.P. and Beal, M.F.
Delayed administration of basic fibroblast growth factor protects against N-methyl-D-aspartate neurotoxicity in neonatal rats (232) 295

Olievier, C.N., see Berkenbosch, A. (232) 21
Olverman, H.J., see MacKinnon, A.C. (232) 79

Page, C.P., see Riccio, M.M. (232) 89
Pain, D., see Guard, S. (232) 287
Papa, S.M., Engber, T.M., Boldry, R.C. and Chase, T.N.
Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists (232) 247
Pauletzki, J.G., Sharkey, K.A., Davison, J.S., Bomzon, A. and Shaffer, E.A.
Involvement of L-arginine-nitric oxide pathways in neural relaxation of the sphincter of Oddi (232) 263
Pérez-Vizcaíno, F., Carrón, R., Delpón, E., Duarte, J. and Tamargo, J.
Effects of (S)-nafenodone on $^{45}Ca^{2+}$ fluxes and contractions in rat isolated vascular smooth muscle (232) 105
Picard, P., Boucher, S., Regoli, D., Gitter, B.D., Howbert, J.J. and Couture, R.
Use of non-peptide tachykinin receptor antagonists to substantiate the involvement of NK_1 and NK_2 receptors in a spinal nociceptive reflex in the rat (232) 255
Pietrasiewicz, T., see Czechowska, G. (232) 59
Prouteau, M., see Angel, I. (232) 139
Purnyn, S., see Knoper, S.R. (232) 65

Regoli, D., see Picard, P. (232) 255
Riccio, M.M., Manzini, S. and Page, C.P.
The effect of neonatal capsaicin on the development of bronchial hyperresponsiveness in allergic rabbits (232) 89
Rompré, P.-P. and Boye, S.M.
Opposite effects of mesencephalic microinjections of cholecystokinin octapeptide and neurotensin-(1–13) on brain stimulation reward (232) 299
Rotondo, S., De Gaetano, G. and Cerletti, C.
Antiplatelet activity of 2-(6-carboxyhexyl)-3-n-hexylcyclohexylamine (IBI P-05006), a thromboxane receptor antagonist (232) 41
Rupreht, J., see Berkenbosch, A. (232) 21

Saito, M., see Majima, M. (232) 181
Sawyer, B.D., see Shannon, H.E. (232) 47
Schechter, M.D. and Meehan, S.M.
Conditioned place preference produced by the psychostimulant cathinone (232) 135
Scheurink, A.J.W., see Benthem, L. (232) 279
Schoemaker, H., see Angel, I. (232) 139
Shaffer, E.A., see Pauletzki, J.G. (232) 263
Shannon, H.E., Sawyer, B.D., Bemis, K.G., Bymaster, F.P., Heath, I., Mitch, C.H. and Ward, J.S.
Muscarinic M_1 receptor agonist actions of muscarinic receptor agonists in rabbit vas deferens (232) 47

Sharkey, K.A., see Pauletzki, J.G. (232) 263
Shima, C., see Majima, M. (232) 181
Shirakawa, O., see Tarazi, F.I. (232) 71
Sim, M.K., see Kuttan, S.C. (232) 173
Sneddon, P., see Furman, B.L. (232) 29
Spedding, M., see MacKinnon, A.C. (232) 79
Spinazzé, A., see Gully, D. (232) 13
Stabentheiner, A., see Lippe, I.T. (232) 113
Steffens, A.B., see Benthem, L. (232) 279
Stewart, M., see MacKinnon, A.C. (232) 79

Tamargo, J., see Pérez-Vizcaíno, F. (232) 105
Tamminga, C.A., see Tarazi, F.I. (232) 71
Tamura, K., Mutabagani, K. and Wood, J.D.
Analysis of a nonpeptide antagonist for substance P on myenteric neurons of guinea-pig small intestine (232) 235
Tarazi, F.I., Shirakawa, O. and Tamminga, C.A.
Low dose raclopride spares the extrapyramidal system in rat brain from metabolic effects (232) 71
Telegdy, G., see Bidzseranova, A. (232) 305
Ter Laak, A.M., Donné-Op den Kelder, G.M., Bast, A. and Timmerman, H.
Is there a difference in the affinity of histamine H_1 receptor antagonists for CNS and peripheral receptors? An in vitro study (232) 199
Timmerman, H., see Ter Laak, A.M. (232) 199
Tokuyama, K., see Kato, M. (232) 7
Turski, W.A., see Czechowska, G. (232) 59

Van der Leest, J., see Benthem, L. (232) 279
Van der Valk, J.B.F. and Vijverberg, H.P.M.
Chronic sabeluzole treatment of cultured rat cerebellar granule cells reduces N-methyl-D-aspartate-induced inward current (232) 131
Van Erp, A.M.M., Kruk, M.R. and De Kloet, E.R.
Induction of grooming in resting rats by intracerebroventricular oxytocin but not by adrenocorticotropic hormone-(1–24) and α-melanocyte-stimulating hormone (232) 217
Varga, J., see Bidzseranova, A. (232) 305
Vargas, M.L., see Martinez-Piñero, M.G. (232) 191
Vijverberg, H.P.M., see Van der Valk, J.B.F. (232) 131
Vilhardt, H., Barth, T., Melin, P. and Aurell, C.-J.
Antidiuretic activity and release of Factor VIII by vasopressin analogues (232) 223
Villanueva, L., see Bouhassira, D. (232) 207

Wallace, J.L., see McCafferty, D.-M. (232) 169
Ward, J.S., see Shannon, H.E. (232) 47
Watling, K.J., see Guard, S. (232) 287
Weiss, R.M., see Yoshida, M. (232) 159
Wilson, L.M., see Currie, P.J. (232) 227
Wolf, G., see Fischer, S. (232) 121
Wolsink, J.G., see Berkenbosch, A. (232) 21
Wood, J.D., see Tamura, K. (232) 235

Yamada, S., Yokoo, H. and Nishi, S.
Chronic treatment with haloperidol modifies the sensitivity of autoreceptors that modulate dopamine release in rat striatum (232) 1
Yokoo, H., see Yamada, S. (232) 1
Yoshida, M., Latifpour, J. and Weiss, R.M.
Age-related changes in Ca^{2+} channel antagonist receptors in rabbit lower urinary tract (232) 159

Zhang, H., see Lee, T.H. (232) 125
Zijlstra, W.G., see Benthem, L. (232) 279

European Journal of Pharmacology, 232 (1993) 331–338
© 1993 Elsevier Science Publishers B.V. All rights reserved 0014-2999/93/$06.00

Key word index

ACTH (adrenocorticotropic hormone)
α-MSH (α-melanocyte-stimulating hormone); Behavioural state; Grooming; Oxytocin; (Intracerebroventricular infusions) (Van Erp, A.M.M. (232) 217)

Adenosine analogs
TNF (tumor necrosis factor); Endothelium; Polymorphonuclear leukocytes; Anti-inflammatory agents (Cerri, M.A. (232) 291)

Adherence
Inflammation; Microcirculation; Neutrophils; PAF (platelet-activating factor, PAF-acether) (McCafferty, D.-M. (232) 169)

α_2-Adrenoceptors
Feeding; Obese mice; Norepinephrine; Clonidine; Yohimbine (Currie, P.J. (232) 227)

Allergen
Capsaicin; Bronchial hyperresponsiveness; Neonatal treatment (Riccio, M.M. (232) 89)

Alveolar macrophages
Superoxide anion; PAF (platelet-activating factor, PAF-acether); Polymorphonuclear leukocytes; Thromboxane A_2; (Guinea-pig) (Kato, M. (232) 7)

[^{3}H]p-Aminoclonidine
[^{3}H]Idazoxan; Imidazoline binding sites; RS-15385-197; Kidney (rat) (MacKinnon, A.C. (232) 79)

Amnesia
pBNP-32 (porcine brain natriuretic peptide-32); Electroconvulsive shock; (Receptor blockers) (Bidzseranova, A. (232) 305)

AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)
Excitotoxicity; Mg^{2+}; Hippocampus; Neurodegeneration; Neuroprotection (Fischer, S. (232) 121)

d-Amphetamine
Dopamine; Substantia nigra; Autoreceptors; Single-unit recording; (In vitro) (Lee, T.H. (232) 125)

Amylase secretion
SR 27897; CCK_A receptors; Gastric emptying; Gall bladder emptying (Gully, D. (232) 13)

Angiotensin II
Receptor affinity; Smooth muscle (vascular) (Kuttan, S.C. (232) 173)

Anticonvulsant drugs
Ucb L059; Seizures; Epilepsy; Piracetam; Valproate (Löscher, W. (232) 147)

Antidepressants
(S)-Nafenodone; Aorta (rat); $^{45}Ca^{2+}$ movements (Pérez-Vizcaíno, F. (232) 105)

Litoxetine; Emesis; 5-HT (5-hydroxytryptamine, serotonin) (Angel, I. (232) 139)

5-HT uptake; Fluvoxamine; Raphe nuclei; Frontal cortex; Microdialysis (in vivo) (Bel, N. (232) 326)

Antidiuretic activity
Factor VIII; Vasopressin analogues; Monkey (Vilhardt, H. (232) 223)

Anti-inflammatory agents
Adenosine analogs; TNF (tumor necrosis factor); Endothelium; Polymorphonuclear leukocytes (Cerri, M.A. (232) 291)

Antiplatelet compound
IBI P-05006; Platelets; Thromboxane A_2/prostaglandin endoperoxides receptor antagonists (Rotondo, S. (232) 41)

Aorta (rat)
(S)-Nafenodone; $^{45}Ca^{2+}$ movements; Antidepressants (Pérez-Vizcaíno, F. (232) 105)

Apomorphine
Dopamine release; Striatum; Haloperidol; Sulpiride; (Chronic treatment) (Yamada, S. (232) 1)

Autoreceptors
d-Amphetamine; Dopamine; Substantia nigra; Single-unit recording; (In vitro) (Lee, T.H. (232) 125)

BAY k 8644
Ca^{2+} channels; Verapamil; Nimodipine; Morphine; Hypothalamus-pituitary-adrenocortical axis; Hypothalamic monoamines; Corticosterone (Martinez-Piñero, M.G. (232) 191)

Behavioural state
ACTH (adrenocorticotropic hormone); α-MSH (α-melanocyte-stimulating hormone); Grooming; Oxytocin; (Intracerebroventricular infusions) (Van Erp, A.M.M. (232) 217)

Benzamides
Raclopride; Cerebral glucose metabolism (regional); Neuroleptics (Tarazi, F.I. (232) 71)

Bladder
Ontogeny; Ca^{2+} channel antagonists; Dihydropyridine; Urethra (Yoshida, M. (232) 159)

Bladder (rabbit, hamster)
Tachykinin; Neurokinin A; Neurokinin receptor subtypes; Tachykinin receptor antagonists (Guard, S. (232) 287)

Blood vessels
Neuropeptide Y; Neuropeptide Y_1 receptors; Neuropeptide Y_2 receptors; Vascular neuropeptide Y receptors; Vas deferens (Grundemar, L. (232) 271)

pBNP-32 (porcine brain natriuretic peptide-32)
Electroconvulsive shock; Amnesia; (Receptor blockers) (Bidzseranova, A. (232) 305)

Bradykinin
Poststatin; Degradation pathway; Urine; Kininase (Majima, M. (232) 181)

Breathing
Ventilatory response; CO_2; Chemoreflex (central); Chemoreflex (peripheral); (Anaesthetized cat) (Berkenbosch, A. (232) 21)

Bronchial hyperresponsiveness
Capsaicin; Neonatal treatment; Allergen (Riccio, M.M. (232) 89)

Ca^{2+} channel antagonists
Ontogeny; Dihydropyridine; Urethra; Bladder (Yoshida, M. (232) 159)

Ca^{2+} channels
Verapamil; Nimodipine; BAY k 8644; Morphine; Hypothalamus-pituitary-adrenocortical axis; Hypothalamic monoamines; Corticosterone (Martinez-Piñero, M.G. (232) 191)

Calorimetry (indirect)
Serotonergic mechanisms (peripheral); Glucose; Free fatty acids; Insulin; Exercise; (Rat); (Baseline conditions) (Benthem, L. (232) 279)

$^{45}Ca^{2+}$ movements
(S)-Nafenodone; Aorta (rat); Antidepressants (Pérez-Vizcaíno, F. (232) 105)

Capsaicin
Bronchial hyperresponsiveness; Neonatal treatment; Allergen (Riccio, M.M. (232) 89)

Carbachol
Muscarinic M_1 receptors; Muscarinic M_1 receptor agonists; Vas deferens (rabbit); Hippocampus (rat); Pirenzepine; Oxotremorine-M; McN-A-343 (Shannon, H.E. (232) 47)

Cathinone
Conditioned place preference; Dopamine; Locomotion; (Rat) (Schechter, M.D. (232) 135)

CCK_A receptors
SR 27897; Gastric emptying; Gall bladder emptying; Amylase secretion (Gully, D. (232) 13)

Cholecystokinin; Slow depolarization; Sympathetic neurons (mammalian); Electrophysiology; Primary cell culture (Knoper, S.R. (232) 65)

Cerebellum
Sabeluzole; NMDA receptors; Glutamate; Granule cells; Voltage clamp (Van der Valk, J.B.F. (232) 131)

Histamine H_1 receptors; Histamine H_1 receptor antagonists; [^{3}H]Mepyramine; Lung tissue; Selectivity; Sedation (Ter Laak, A.M. (232) 199)

Cerebral glucose metabolism (regional)
Raclopride; Benzamides; Neuroleptics (Tarazi, F.I. (232) 71)

CGP 37849
Electroshock (maximal); CGP 39551; Valproate; Seizures (Czechowska, G. (232) 59)

CGP 39551
Electroshock (maximal); CGP 37849; Valproate; Seizures (Czechowska, G. (232) 59)

Chemoreflex (central)
Breathing; Ventilatory response; CO_2; Chemoreflex (peripheral); (Anaesthetized cat) (Berkenbosch, A. (232) 21)

Chemoreflex (peripheral)
Breathing; Ventilatory response; CO_2; Chemoreflex (central); (Anaesthetized cat) (Berkenbosch, A. (232) 21)

Cholecystokinin
CCK_A receptors; Slow depolarization; Sympathetic neurons (mammalian); Electrophysiology; Primary cell culture (Knoper, S.R. (232) 65)

Nitric oxide (NO); Non-adrenergic, non-cholinergic (NANC) nerves; Sphincter of Oddi; Histamine (Pauletzki, J.G. (232) 263)

Dopamine; Neurotensin; Reward; Ventral tegmental area (Rompré, P.-P. (232) 299)

Clonidine
Galanin; M35; Islets of Langerhans (isolated); Insulin secretion; Somatostatin (Gregersen, S. (232) 35)

Feeding; Obese mice; Norepinephrine; Yohimbine; α_2-Adrenoceptors (Currie, P.J. (232) 227)

CO_2
Breathing; Ventilatory response; Chemoreflex (central); Chemoreflex (peripheral); (Anaesthetized cat) (Berkenbosch, A. (232) 21)

Conditioned place preference
Cathinone; Dopamine; Locomotion; (Rat) (Schechter, M.D. (232) 135)

Corticosterone
Ca^{2+} channels; Verapamil; Nimodipine; BAY k 8644; Morphine; Hypothalamus-pituitary-adrenocortical axis; Hypothalamic monoamines (Martinez-Piñero, M.G. (232) 191)

Cutaneous vasodilatation
Mustard oil; Neurogenic inflammation; Infrared emission thermography; Vascular permeability; Nitric oxide (NO); L-NAME (N^G-nitro-L-arginine methyl ester) (Lippe, I.T. (232) 113)

Degradation pathway
Poststatin; Bradykinin; Urine; Kininase (Majima, M. (232) 181)

Descending inhibitory controls
Pain; Spinal cord; Morphine; Rostral ventromedial medulla (Bouhassira, D. (232) 207)

Desipramine
6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine); 6-Hydroxydopamine (6-OHDA); Nomifensine; Neurotoxicity (Evans, J. (232) 241)

Diabetes
Streptozotocin; Endothelium; Mesenteric artery; Vasodilatation (Furman, B.L. (232) 29)

Dihydropyridine
Ontogeny; Ca^{2+} channel antagonists; Urethra; Bladder (Yoshida, M. (232) 159)

Dopamine
d-Amphetamine; Substantia nigra; Autoreceptors; Single-unit recording; (In vitro) (Lee, T.H. (232) 125)

Cathinone; Conditioned place preference; Locomotion; (Rat) (Schechter, M.D. (232) 135)

Cholecystokinin; Neurotensin; Reward; Ventral tegmental area (Rompré, P.-P. (232) 299)

Dopamine release
Striatum; Haloperidol; Apomorphine; Sulpiride; (Chronic treatment) (Yamada, S. (232) 1)

Electroconvulsive shock
pBNP-32 (porcine brain natriuretic peptide-32); Amnesia; (Receptor blockers) (Bidzseranova, A. (232) 305)

Electrophysiology
Cholecystokinin; CCK_A receptors; Slow depolarization; Sympathetic neurons (mammalian); Primary cell culture (Knoper, S.R. (232) 65)

Electroshock (maximal)
CGP 37849; CGP 39551; Valproate; Seizures (Czechowska, G. (232) 59)

Emesis
Litoxetine; Antidepressants; 5-HT (5-hydroxytryptamine, serotonin) (Angel, I. (232) 139)

Endothelium
Diabetes; Streptozotocin; Mesenteric artery; Vasodilatation (Furman, B.L. (232) 29)

Adenosine analogs; TNF (tumor necrosis factor); Polymorphonuclear leukocytes; Anti-inflammatory agents (Cerri, M.A. (232) 291)

Enteric nervous system
Intestine; Ganglia; Myenteric plexus; Substance P; Tachykinins (Tamura, K. (232) 235)

Epilepsy
Ucb L059; Seizures; Piracetam; Valproate; Anticonvulsant drugs (Löscher, W. (232) 147)

Excitatory amino acids
Glutamate receptors; Parkinson's disease; Neuroleptics (Papa, S.M. (232) 247)

Excitotoxicity
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Mg^{2+}; Hippocampus; Neurodegeneration; Neuroprotection (Fischer, S. (232) 121)

Excitotoxicity (neonate)
bFGF (basic fibroblast growth factor); NMDA (N-methyl-D-aspartate); Neuroprotection (Nozaki, K. (232) 295)

Exercise
Serotonergic mechanisms (peripheral); Glucose; Free fatty acids; Insulin; Calorimetry (indirect); (Rat); (Baseline conditions) (Benthem, L. (232) 279)

Factor VIII
Antidiuretic activity; Vasopressin analogues; Monkey (Vilhardt, H. (232) 223)

Feeding
Obese mice; Norepinephrine; Clonidine; Yohimbine; α_2-Adrenoceptors (Currie, P.J. (232) 227)

bFGF (basic fibroblast growth factor)
NMDA (N-methyl-D-aspartate); Excitotoxicity (neonate); Neuroprotection (Nozaki, K. (232) 295)

Fluvoxamine
5-HT uptake; Antidepressants; Raphe nuclei; Frontal cortex; Microdialysis (in vivo) (Bel, N. (232) 326)

Free fatty acids
Serotonergic mechanisms (peripheral); Glucose; Insulin; Calorimetry (indirect); Exercise; (Rat); (Baseline conditions) (Benthem, L. (232) 279)

Frontal cortex
5-HT uptake; Fluvoxamine; Antidepressants; Raphe nuclei; Microdialysis (in vivo) (Bel, N. (232) 326)

Galanin
M35; Islets of Langerhans (isolated); Insulin secretion; Clonidine; Somatostatin (Gregersen, S. (232) 35)

Gall bladder emptying
SR 27897; CCK_A receptors; Gastric emptying; Amylase secretion (Gully, D. (232) 13)

Ganglia
Intestine; Enteric nervous system; Myenteric plexus; Substance P; Tachykinins (Tamura, K. (232) 235)

Gastric emptying
SR 27897; CCK_A receptors; Gall bladder emptying; Amylase secretion (Gully, D. (232) 13)

Glucose
Serotonergic mechanisms (peripheral); Free fatty acids; Insulin; Calorimetry (indirect); Exercise; (Rat); (Baseline conditions) (Benthem, L. (232) 279)

Glutamate
Sabeluzole; NMDA receptors; Cerebellum; Granule cells; Voltage clamp (Van der Valk, J.B.F. (232) 131)

Glutamate receptors
Excitatory amino acids; Parkinson's disease; Neuroleptics (Papa, S.M. (232) 247)

Granule cells
Sabeluzole; NMDA receptors; Glutamate; Cerebellum; Voltage clamp (Van der Valk, J.B.F. (232) 131)

Grooming
ACTH (adrenocorticotropic hormone); α-MSH (α-melanocyte-stimulating hormone); Behavioural state; Oxytocin; (Intracerebroventricular infusions) (Van Erp, A.M.M. (232) 217)

Haloperidol
Dopamine release; Striatum; Apomorphine; Sulpiride; (Chronic treatment) (Yamada, S. (232) 1)

Hippocampus
Excitotoxicity; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Mg^{2+}; Neurodegeneration; Neuroprotection (Fischer, S. (232) 121)

Hippocampus (rat)
Muscarinic M_1 receptors; Muscarinic M_1 receptor agonists; Vas deferens (rabbit); Pirenzepine; Oxotremorine-M; Carbachol; McN-A-343 (Shannon, H.E. (232) 47)

Histamine
Nitric oxide (NO); Cholecystokinin; Non-adrenergic, non-cholinergic (NANC) nerves; Sphincter of Oddi (Pauletzki, J.G. (232) 263)

Histamine H_1 receptor antagonists
Histamine H_1 receptors; [^{3}H]Mepyramine; Lung tissue; Cerebellum; Selectivity; Sedation (Ter Laak, A.M. (232) 199)

Histamine H_1 receptors
Histamine H_1 receptor antagonists; [^{3}H]Mepyramine; Lung tissue; Cerebellum; Selectivity; Sedation (Ter Laak, A.M. (232) 199)

Histamine H_3 receptors
(R)-α-Methylhistamine; Thioperamide; Water consumption; (Rat) (Clapham, J. (232) 99)

5-HT (5-hydroxytryptamine, serotonin)
Litoxetine; Antidepressants; Emesis (Angel, I. (232) 139)

5-HT uptake
Fluvoxamine; Antidepressants; Raphe nuclei; Frontal cortex; Microdialysis (in vivo) (Bel, N. (232) 326)

6-Hydroxydopamine (6-OHDA)
6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine); Nomifensine; Desipramine; Neurotoxicity (Evans, J. (232) 241)

6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine)
6-Hydroxydopamine (6-OHDA); Nomifensine; Desipramine; Neurotoxicity (Evans, J. (232) 241)

Hypothalamic monoamines
Ca^{2+} channels; Verapamil; Nimodipine; BAY k 8644; Morphine; Hypothalamus-pituitary-adrenocortical axis; Corticosterone (Martinez-Piñero, M.G. (232) 191)

Hypothalamus-pituitary-adrenocortical axis
Ca^{2+} channels; Verapamil; Nimodipine; BAY k 8644; Morphine; Hypothalamic monoamines; Corticosterone (Martinez-Piñero, M.G. (232) 191)

IBI P-85006
Antiplatelet compound; Platelets; Thromboxane A_2/prostaglandin endoperoxides receptor antagonists (Rotondo, S. (232) 41)

[^{3}H]Idazoxan
[^{3}H]p-Aminoclonidine; Imidazoline binding sites; RS-15385-197; Kidney (rat) (MacKinnon, A.C. (232) 79)

Imidazoline binding sites
[^{3}H]p-Aminoclonidine; [^{3}H]Idazoxan; RS-15385-197; Kidney (rat) (MacKinnon, A.C. (232) 79)

Inflammation
Adherence; Microcirculation; Neutrophils; PAF (platelet-activating factor, PAF-acether) (McCafferty, D.-M. (232) 169)

Infrared emission thermography
Mustard oil; Neurogenic inflammation; Cutaneous vasodilatation; Vascular permeability; Nitric oxide (NO); L-NAME (N^G-nitro-L-arginine methyl ester) (Lippe, I.T. (232) 113)

Insulin
Serotonergic mechanisms (peripheral); Glucose; Free fatty acids; Calorimetry (indirect); Exercise; (Rat); (Baseline conditions) (Benthem, L. (232) 279)

Insulin secretion
Galanin; M35; Islets of Langerhans (isolated); Clonidine; Somatostatin (Gregersen, S. (232) 35)

Intestine
Ganglia; Enteric nervous system; Myenteric plexus; Substance P; Tachykinins (Tamura, K. (232) 235)

Islets of Langerhans (isolated)
Galanin; M35; Insulin secretion; Clonidine; Somatostatin (Gregersen, S. (232) 35)

Kidney (rat)
[^{3}H]p-Aminoclonidine; [^{3}H]Idazoxan; Imidazoline binding sites; RS-15385-197 (MacKinnon, A.C. (232) 79)

Kininase
Poststatin; Bradykinin; Degradation pathway; Urine (Majima, M. (232) 181)

Litoxetine
Antidepressants; Emesis; 5-HT (5-hydroxytryptamine, serotonin) (Angel, I. (232) 139)

Locomotion
Cathinone; Conditioned place preference; Dopamine; (Rat) (Schechter, M.D. (232) 135)

Lung tissue
Histamine H_1 receptors; Histamine H_1 receptor antagonists; [^{3}H]Mepyramine; Cerebellum; Selectivity; Sedation (Ter Laak, A.M. (232) 199)

M35
Galanin; Islets of Langerhans (isolated); Insulin secretion; Clonidine; Somatostatin (Gregersen, S. (232) 35)

McN-A-343
Muscarinic M_1 receptors; Muscarinic M_1 receptor agonists; Vas deferens (rabbit); Hippocampus (rat); Pirenzepine; Oxotremorine-M; Carbachol (Shannon, H.E. (232) 47)

[^{3}H]Mepyramine
Histamine H_1 receptors; Histamine H_1 receptor antagonists; Lung tissue; Cerebellum; Selectivity; Sedation (Ter Laak, A.M. (232) 199)

Mesenteric artery
Diabetes; Streptozotocin; Endothelium; Vasodilatation (Furman, B.L. (232) 29)

(R)-α-Methylhistamine
Histamine H_3 receptors; Thioperamide; Water consumption; (Rat) (Clapham, J. (232) 99)

Mg^{2+}
Excitotoxicity; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Hippocampus; Neurodegeneration; Neuroprotection (Fischer, S. (232) 121)

Microcirculation
Inflammation; Adherence; Neutrophils; PAF (platelet-activating factor, PAF-acether) (McCafferty, D.-M. (232) 169)

Microdialysis (in vivo)
5-HT uptake; Fluvoxamine; Antidepressants; Raphe nuclei; Frontal cortex (Bel, N. (232) 326)

Monkey
Factor VIII; Antidiuretic activity; Vasopressin analogues (Vilhardt, H. (232) 223)

Morphine
Ca^{2+} channels; Verapamil; Nimodipine; BAY k 8644; Hypothalamus-pituitary-adrenocortical axis; Hypothalamic monoamines; Corticosterone (Martinez-Piñero, M.G. (232) 191)

Pain; Spinal cord; Descending inhibitory controls; Rostral ventromedial medulla (Bouhassira, D. (232) 207)

α-MSH (α-melanocyte-stimulating hormone)
ACTH (adrenocorticotropic hormone); Behavioural state; Grooming; Oxytocin; (Intracerebroventricular infusions) (Van Erp, A.M.M. (232) 217)

Muscarinic M_1 receptor agonists
Muscarinic M_1 receptors; Vas deferens (rabbit); Hippocampus (rat); Pirenzepine; Oxotremorine-M; Carbachol; McN-A-343 (Shannon, H.E. (232) 47)

Muscarinic M_1 receptors
Muscarinic M_1 receptor agonists; Vas deferens (rabbit); Hippocampus (rat); Pirenzepine; Oxotremorine-M; Carbachol; McN-A-343 (Shannon, H.E. (232) 47)

Mustard oil
Neurogenic inflammation; Cutaneous vasodilatation; Infrared emission thermography; Vascular permeability; Nitric oxide (NO); L-NAME (N^G-nitro-L-arginine methyl ester) (Lippe, I.T. (232) 113)

Myenteric plexus
Intestine; Ganglia; Enteric nervous system; Substance P; Tachykinins (Tamura, K. (232) 235)

(S)-Nafenodone
Aorta (rat); $^{45}Ca^{2+}$ movements; Antidepressants (Pérez-Vizcaíno, F. (232) 105)

L-NAME (N^G-nitro-L-arginine methyl ester)
Mustard oil; Neurogenic inflammation; Cutaneous vasodilatation; Infrared emission thermography; Vascular permeability; Nitric oxide (NO) (Lippe, I.T. (232) 113)

Neonatal treatment
Capsaicin; Bronchial hyperresponsiveness; Allergen (Riccio, M.M. (232) 89)

Neurodegeneration
Excitotoxicity; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Mg^{2+}; Hippocampus; Neuroprotection (Fischer, S. (232) 121)

Neurogenic inflammation
Mustard oil; Cutaneous vasodilatation; Infrared emission thermography; Vascular permeability; Nitric oxide (NO); L-NAME (N^G-nitro-L-arginine methyl ester) (Lippe, I.T. (232) 113)

Neurokinin A
Tachykinin; Neurokinin receptor subtypes; Tachykinin receptor antagonists; Bladder (rabbit, hamster) (Guard, S. (232) 287)

Neurokinin receptor antagonists
NK_1 receptors; NK_2 receptors; Spinal cord; Nociception (Picard, P. (232) 255)

Neurokinin receptor subtypes
Tachykinin; Neurokinin A; Tachykinin receptor antagonists; Bladder (rabbit, hamster) (Guard, S. (232) 287)

Neuroleptics
Raclopride; Cerebral glucose metabolism (regional); Benzamides (Tarazi, F.I. (232) 71)

Excitatory amino acids; Glutamate receptors; Parkinson's disease (Papa, S.M. (232) 247)

Neuropeptide Y
Neuropeptide Y_1 receptors; Neuropeptide Y_2 receptors; Vascular neuropeptide Y receptors; Vas deferens; Blood vessels (Grundemar, L. (232) 271)

Neuropeptide Y_1 receptors
Neuropeptide Y; Neuropeptide Y_2 receptors; Vascular neuropeptide Y receptors; Vas deferens; Blood vessels (Grundemar, L. (232) 271)

Neuropeptide Y_2 receptors
Neuropeptide Y; Neuropeptide Y_1 receptors; Vascular neuropeptide Y receptors; Vas deferens; Blood vessels (Grundemar, L. (232) 271)

Neuroprotection
Excitotoxicity; AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid); Mg^{2+}; Hippocampus; Neurodegeneration (Fischer, S. (232) 121)

bFGF (basic fibroblast growth factor); NMDA (N-methyl-D-aspartate); Excitotoxicity (neonate) (Nozaki, K. (232) 295)

Neurotensin
Cholecystokinin; Dopamine; Reward; Ventral tegmental area (Rompré, P.-P. (232) 299)

Neurotoxicity
6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine); 6-Hydroxydopamine (6-OHDA); Nomifensine; Desipramine (Evans, J. (232) 241)

Neutrophils
Inflammation; Adherence; Microcirculation; PAF (platelet-activating factor, PAF-acether) (McCafferty, D.-M. (232) 169)

Nimodipine
Ca^{2+} channels; Verapamil; BAY k 8644; Morphine; Hypothalamus-pituitary-adrenocortical axis; Hypothalamic monoamines; Corticosterone (Martinez-Piñero, M.G. (232) 191)

Nitric oxide (NO)
Mustard oil; Neurogenic inflammation; Cutaneous vasodilatation; Infrared emission thermography; Vascular permeability; L-NAME (N^G-nitro-L-arginine methyl ester) (Lippe, I.T. (232) 113)

Cholecystokinin; Non-adrenergic, non-cholinergic (NANC) nerves; Sphincter of Oddi; Histamine (Pauletzki, J.G. (232) 263)

NK_1 receptors
Neurokinin receptor antagonists; NK_2 receptors; Spinal cord; Nociception (Picard, P. (232) 255)

NK_2 receptors
Neurokinin receptor antagonists; NK_1 receptors; Spinal cord; Nociception (Picard, P. (232) 255)

NMDA (N-methyl-D-aspartate)
bFGF (basic fibroblast growth factor); Excitotoxicity (neonate); Neuroprotection (Nozaki, K. (232) 295)

NMDA receptors
Sabeluzole; Glutamate; Cerebellum; Granule cells; Voltage clamp (Van der Valk, J.B.F. (232) 131)

Nociception
Neurokinin receptor antagonists; NK_1 receptors; NK_2 receptors; Spinal cord (Picard, P. (232) 255)

Nomifensine
6-Hydroxy-DOPA (2,4,5-trihydroxyphenylalanine); 6-Hydroxydopamine (6-OHDA); Desipramine; Neurotoxicity (Evans, J. (232) 241)

Non-adrenergic, non-cholinergic (NANC) nerves
Nitric oxide (NO); Cholecystokinin; Sphincter of Oddi; Histamine (Pauletzki, J.G. (232) 263)

Norepinephrine
Feeding; Obese mice; Clonidine; Yohimbine; α_2-Adrenoceptors (Currie, P.J. (232) 227)

Obese mice
Feeding; Norepinephrine; Clonidine; Yohimbine; α_2-Adrenoceptors (Currie, P.J. (232) 227)

Ontogeny
Ca^{2+} channel antagonists; Dihydropyridine; Urethra; Bladder (Yoshida, M. (232) 159)

Oxotremorine-M
Muscarinic M_1 receptors; Muscarinic M_1 receptor agonists; Vas deferens (rabbit); Hippocampus (rat); Pirenzepine; Carbachol; McN-A-343 (Shannon, H.E. (232) 47)

Oxytocin
ACTH (adrenocorticotropic hormone); α-MSH (α-melanocyte-stimulating hormone); Behavioural state; Grooming; (Intracerebroventricular infusions) (Van Erp, A.M.M. (232) 217)

PAF (platelet-activating factor, PAF-acether)
Superoxide anion; Alveolar macrophages; Polymorphonuclear leukocytes; Thromboxane A_2; (Guinea-pig) (Kato, M. (232) 7)

Inflammation; Adherence; Microcirculation; Neutrophils (McCafferty, D.-M. (232) 169)

Pain
Spinal cord; Morphine; Descending inhibitory controls; Rostral ventromedial medulla (Bouhassira, D. (232) 207)

Parkinson's disease
Excitatory amino acids; Glutamate receptors; Neuroleptics (Papa, S.M. (232) 247)

Piracetam
Ucb L059; Seizures; Epilepsy; Valproate; Anticonvulsant drugs (Löscher, W. (232) 147)

Pirenzepine
Muscarinic M_1 receptors; Muscarinic M_1 receptor agonists; Vas deferens (rabbit); Hippocampus (rat); Oxotremorine-M; Carbachol; McN-A-343 (Shannon, H.E. (232) 47)

Platelets
Antiplatelet compound; IBI P-05006; Thromboxane A_2/prostaglandin endoperoxides receptor antagonists (Rotondo, S. (232) 41)

Polymorphonuclear leukocytes
Superoxide anion; PAF (platelet-activating factor, PAF-acether); Alveolar macrophages; Thromboxane A_2; (Guinea-pig) (Kato, M. (232) 7)

Adenosine analogs; TNF (tumor necrosis factor); Endothelium; Anti-inflammatory agents (Cerri, M.A. (232) 291)

Poststatin
Bradykinin; Degradation pathway; Urine; Kininase (Majima, M. (232) 181)

Primary cell culture
Cholecystokinin; CCK_A receptors; Slow depolarization; Sympathetic neurons (mammalian); Electrophysiology (Knoper, S.R. (232) 65)

Raclopride
Cerebral glucose metabolism (regional); Benzamides; Neuroleptics (Tarazi, F.I. (232) 71)

Raphe nuclei
5-HT uptake; Fluvoxamine; Antidepressants; Frontal cortex; Microdialysis (in vivo) (Bel, N. (232) 326)

Receptor affinity
Angiotensin II; Smooth muscle (vascular) (Kuttan, S.C. (232) 173)

Reward
Cholecystokinin; Dopamine; Neurotensin; Ventral tegmental area (Rompré, P.-P. (232) 299)

Rostral ventromedial medulla
Pain; Spinal cord; Morphine; Descending inhibitory controls (Bouhassira, D. (232) 207)

RS-15385-197
[^{3}H]p-Aminoclonidine; [^{3}H]Idazoxan; Imidazoline binding sites; Kidney (rat) (MacKinnon, A.C. (232) 79)

Sabeluzole
NMDA receptors; Glutamate; Cerebellum; Granule cells; Voltage clamp (Van der Valk, J.B.F. (232) 131)

Sedation
Histamine H_1 receptors; Histamine H_1 receptor antagonists; [^{3}H]Mepyramine; Lung tissue; Cerebellum; Selectivity (Ter Laak, A.M. (232) 199)

Seizures
Electroshock (maximal); CGP 37849; CGP 39551; Valproate (Czechowska, G. (232) 59)

Ucb L059; Epilepsy; Piracetam; Valproate; Anticonvulsant drugs (Löscher, W. (232) 147)

Selectivity
Histamine H_1 receptors; Histamine H_1 receptor antagonists; [^{3}H]Mepyramine; Lung tissue; Cerebellum; Sedation (Ter Laak, A.M. (232) 199)

Serotonergic mechanisms (peripheral)
Glucose; Free fatty acids; Insulin; Calorimetry (indirect); Exercise; (Rat); (Baseline conditions) (Benthem, L. (232) 279)

Single-unit recording
d-Amphetamine; Dopamine; Substantia nigra; Autoreceptors; (In vitro) (Lee, T.H. (232) 125)

Slow depolarization
Cholecystokinin; CCK_A receptors; Sympathetic neurons (mammalian); Electrophysiology; Primary cell culture (Knoper, S.R. (232) 65)

Smooth muscle (vascular)
Angiotensin II; Receptor affinity (Kuttan, S.C. (232) 173)

Somatostatin
Galanin; M35; Islets of Langerhans (isolated); Insulin secretion; Clonidine (Gregersen, S. (232) 35)

Sphincter of Oddi
Nitric oxide (NO); Cholecystokinin; Non-adrenergic, non-cholinergic (NANC) nerves; Histamine (Pauletzki, J.G. (232) 263)

Spinal cord
Pain; Morphine; Descending inhibitory controls; Rostral ventromedial medulla (Bouhassira, D. (232) 207)

Neurokinin receptor antagonists; NK_1 receptors; NK_2 receptors; Nociception (Picard, P. (232) 255)

SR 27897
CCK_A receptors; Gastric emptying; Gall bladder emptying; Amylase secretion (Gully, D. (232) 13)

Streptozotocin
Diabetes; Endothelium; Mesenteric artery; Vasodilatation (Furman, B.L. (232) 29)

Striatum
Dopamine release; Haloperidol; Apomorphine; Sulpiride; (Chronic treatment) (Yamada, S. (232) 1)

Substance P
Intestine; Ganglia; Enteric nervous system; Myenteric plexus; Tachykinins (Tamura, K. (232) 235)

Substantia nigra
d-Amphetamine; Dopamine; Autoreceptors; Single-unit recording; (In vitro) (Lee, T.H. (232) 125)

Sulpiride
Dopamine release; Striatum; Haloperidol; Apomorphine; (Chronic treatment) (Yamada, S. (232) 1)

Superoxide anion
PAF (platelet-activating factor, PAF-acether); Alveolar macrophages; Polymorphonuclear leukocytes; Thromboxane A_2; (Guinea-pig) (Kato, M. (232) 7)

Sympathetic neurons (mammalian)
Cholecystokinin; CCK_A receptors; Slow depolarization; Electrophysiology; Primary cell culture (Knoper, S.R. (232) 65)

Tachykinin
Neurokinin A; Neurokinin receptor subtypes; Tachykinin receptor antagonists; Bladder (rabbit, hamster) (Guard, S. (232) 287)

Tachykinin receptor antagonists
Tachykinin; Neurokinin A; Neurokinin receptor subtypes; Bladder (rabbit, hamster) (Guard, S. (232) 287)

Tachykinins
Intestine; Ganglia; Enteric nervous system; Myenteric plexus; Substance P (Tamura, K. (232) 235)

Thioperamide
Histamine H_3 receptors; (R)-α-Methylhistamine; Water consumption; (Rat) (Clapham, J. (232) 99)

Thromboxane A_2
Superoxide anion; PAF (platelet-activating factor, PAF-acether); Alveolar macrophages; Polymorphonuclear leukocytes; (Guinea-pig) (Kato, M. (232) 7)

Thromboxane A_2/prostaglandin endoperoxides receptor antagonists
Antiplatelet compound; IBI P-05006; Platelets (Rotondo, S. (232) 41)

TNF (tumor necrosis factor)
Adenosine analogs; Endothelium; Polymorphonuclear leukocytes; Anti-inflammatory agents (Cerri, M.A. (232) 291)

Ucb L059
Seizures; Epilepsy; Piracetam; Valproate; Anticonvulsant drugs (Löscher, W. (232) 147)

Urethra
Ontogeny; Ca^{2+} channel antagonists; Dihydropyridine; Bladder (Yoshida, M. (232) 159)

Urine
Poststatin; Bradykinin; Degradation pathway; Kininase (Majima, M. (232) 181)

Valproate
Electroshock (maximal); CGP 37849; CGP 39551; Seizures (Czechowska, G. (232) 59)

Ucb L059; Seizures; Epilepsy; Piracetam; Anticonvulsant drugs (Löscher, W. (232) 147)

Vascular neuropeptide Y receptors
Neuropeptide Y; Neuropeptide Y_1 receptors; Neuropeptide Y_2 receptors; Vas deferens; Blood vessels (Grundemar, L. (232) 271)

Vascular permeability
Mustard oil; Neurogenic inflammation; Cutaneous vasodilatation; Infrared emission thermography; Nitric oxide (NO); L-NAME (N^G-nitro-L-arginine methyl ester) (Lippe, I.T. (232) 113)

Vas deferens
Neuropeptide Y; Neuropeptide Y_1 receptors; Neuropeptide Y_2 receptors; Vascular neuropeptide Y receptors; Blood vessels (Grundemar, L. (232) 271)

Vas deferens (rabbit)
Muscarinic M_1 receptors; Muscarinic M_1 receptor agonists; Hippocampus (rat); Pirenzepine; Oxotremorine-M; Carbachol; McN-A-343 (Shannon, H.E. (232) 47)

Vasodilatation
Diabetes; Streptozotocin; Endothelium; Mesenteric artery (Furman, B.L. (232) 29)

Vasopressin analogues
Factor VIII; Antidiuretic activity; Monkey (Vilhardt, H. (232) 223)

Ventilatory response
Breathing; CO_2; Chemoreflex (central); Chemoreflex (peripheral); (Anaesthetized cat) (Berkenbosch, A. (232) 21)

Ventral tegmental area
Cholecystokinin; Dopamine; Neurotensin; Reward (Rompré, P.-P. (232) 299)

Verapamil
Ca^{2+} channels; Nimodipine; BAY k 8644; Morphine; Hypothalamus-pituitary-adrenocortical axis; Hypothalamic monoamines; Corticosterone (Martinez-Piñero, M.G. (232) 191)

Voltage clamp
Sabeluzole; NMDA receptors; Glutamate; Cerebellum; Granule cells (Van der Valk, J.B.F. (232) 131)

Water consumption
Histamine H_3 receptors; (R)-α-Methylhistamine; Thioperamide; (Rat) (Clapham, J. (232) 99)

Yohimbine
Feeding; Obese mice; Norepinephrine; Clonidine; α_2-Adrenoceptors (Currie, P.J. (232) 227)